1. Home
  2. LGND vs NVST Comparison

LGND vs NVST Comparison

Compare LGND & NVST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LGND
  • NVST
  • Stock Information
  • Founded
  • LGND 1987
  • NVST 2018
  • Country
  • LGND United States
  • NVST United States
  • Employees
  • LGND 68
  • NVST N/A
  • Industry
  • LGND Biotechnology: Pharmaceutical Preparations
  • NVST Medical/Dental Instruments
  • Sector
  • LGND Health Care
  • NVST Health Care
  • Exchange
  • LGND Nasdaq
  • NVST Nasdaq
  • Market Cap
  • LGND 3.2B
  • NVST 3.4B
  • IPO Year
  • LGND 1992
  • NVST 2019
  • Fundamental
  • Price
  • LGND $184.44
  • NVST $20.89
  • Analyst Decision
  • LGND Strong Buy
  • NVST Buy
  • Analyst Count
  • LGND 8
  • NVST 12
  • Target Price
  • LGND $144.71
  • NVST $20.91
  • AVG Volume (30 Days)
  • LGND 139.7K
  • NVST 1.8M
  • Earning Date
  • LGND 08-05-2025
  • NVST 10-30-2025
  • Dividend Yield
  • LGND N/A
  • NVST N/A
  • EPS Growth
  • LGND N/A
  • NVST N/A
  • EPS
  • LGND N/A
  • NVST 0.31
  • Revenue
  • LGND $181,488,000.00
  • NVST $2,552,900,000.00
  • Revenue This Year
  • LGND $18.41
  • NVST $6.47
  • Revenue Next Year
  • LGND $18.87
  • NVST $3.25
  • P/E Ratio
  • LGND N/A
  • NVST $64.06
  • Revenue Growth
  • LGND 53.40
  • NVST 0.76
  • 52 Week Low
  • LGND $81.74
  • NVST $14.22
  • 52 Week High
  • LGND $129.90
  • NVST $23.00
  • Technical
  • Relative Strength Index (RSI)
  • LGND 58.00
  • NVST 59.17
  • Support Level
  • LGND $182.87
  • NVST $19.90
  • Resistance Level
  • LGND $194.44
  • NVST $20.64
  • Average True Range (ATR)
  • LGND 5.35
  • NVST 0.46
  • MACD
  • LGND -0.77
  • NVST 0.09
  • Stochastic Oscillator
  • LGND 40.05
  • NVST 88.49

About LGND Ligand Pharmaceuticals Incorporated

Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.

About NVST Envista Holdings Corporation

Envista Holdings Corp is a dental products company. It develops, manufactures, and markets portfolios of dental consumables, equipment, and services to dental professionals. The company's business consists of two segments; Specialty Products & Technologies and Equipment & Consumables. The company's Specialty Products & Technologies segment, which derives key revenue, develops, manufactures, and markets dental implant systems, including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, and lab products. Geographically, the company generates a majority of its revenue from North America, followed by Western Europe and other developed and emerging markets.

Share on Social Networks: